Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.
1. Type I risk factor for tardive dyskinesia is defined as a risk leading primarily to a reversible form, while Type II factors to irreversible forms. 2. Central anticholinergic drugs appear as the prototype of Type I drug factor which increased the clinical manifestations of the disorder, but not its overall incidence. 3. Clinical investigations of dopamine agonists suggest an important role for them in clinical management and understanding of neuroleptic-induced supersensitivity disorder. 4. We would like to propose a new classification of neuroleptics. Type I neuroleptics (estrogens, diphenylbutylpiperidines) are associated with milder and reversible dyskinesia, while Type II (Classical neuroleptics) with severe and irreversible forms.
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology*; D004958:Estradiol / Q000009:adverse effects; D006801:Humans; D010276:Parasympatholytics / Q000009:adverse effects*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D012306:Risk
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D011954:Receptors, Dopamine; D004958:Estradiol; D004298:Dopamine